Wilding G - Search Results

1

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.

Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G. Liu G, et al. Among authors: wilding g. Invest New Drugs. 2003 Aug;21(3):367-72. doi: 10.1023/a:1025437115182. Invest New Drugs. 2003. PMID: 14578686 Clinical Trial.

2

Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels.

Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT. Bailey HH, et al. Among authors: wilding g. Cancer Res. 1992 Sep 15;52(18):5115-8. Cancer Res. 1992. PMID: 1355406

3

The importance of steroid hormones in prostate cancer.

Wilding G. Wilding G. Cancer Surv. 1992;14:113-30. Cancer Surv. 1992. PMID: 1423327 Review.

4

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.

Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Bailey H, et al. Among authors: wilding g. Invest New Drugs. 1992 Nov;10(4):279-87. doi: 10.1007/BF00944182. Invest New Drugs. 1992. PMID: 1487401 Clinical Trial.

5

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Bailey H, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Grem JL, Spriggs DR. Bailey H, et al. Among authors: wilding g. Cancer Chemother Pharmacol. 1992;30(4):297-302. doi: 10.1007/BF00686299. Cancer Chemother Pharmacol. 1992. PMID: 1643698 Clinical Trial.

6

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G. Bailey H, et al. Among authors: wilding g. Cancer Res. 1991 Feb 15;51(4):1105-8. Cancer Res. 1991. PMID: 1705165 Clinical Trial.

7

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

Bailey H, Mulcahy RT, Tutsch KD, Rozental JM, Alberti D, Arzoomanian RZ, Tombes MB, Trump DL, Wilding G. Bailey H, et al. Among authors: wilding g. Cancer Res. 1991 Feb 15;51(4):1099-104. Cancer Res. 1991. PMID: 1825475 Clinical Trial.

8

Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta.

Wilding G. Wilding G. Cancer Surv. 1991;11:147-63. Cancer Surv. 1991. PMID: 1841749 Review.

9

Endocrine control of prostate cancer.

Wilding G. Wilding G. Cancer Surv. 1995;23:43-62. Cancer Surv. 1995. PMID: 7621473 Review.

10

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. Berlin J, et al. Among authors: wilding g. Invest New Drugs. 1994;12(2):137-41. doi: 10.1007/BF00874444. Invest New Drugs. 1994. PMID: 7860231 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

550 results

Search Page

Filters